Paramvir Sidhu, MD
Rheumatology · Goodyear, AZNPI 1124220116
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Amgen at 31.3% of the total. Reporting peaked in 2022 at $9,632 and has fallen 90.8% since, to $883 in 2024.
Across 331 payments — averaging $65.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$7K
- Novartis$4K
- Aurinia Pharma U.S., Inc.$4K
- UCB, Inc.$4K
- AbbVie$858
- Actelion Pharmaceuticals US, Inc.$500
- plus $2K from 14 others
Across 21 payments — averaging $37,634 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$731K
- AbbVie$26K
- GSK$20K
- UCB SA$13K
What the payments were for
- Consulting fees$10,03546%
- Speaking & faculty fees$3,39016%
- Travel & lodging$2281%
- Food & beverage$7,86736%
- Education$810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 92 | $6,759 |
| Novartis | 23 | $3,972 |
| Aurinia Pharma U.S., Inc. | 6 | $3,697 |
| UCB, Inc. | 21 | $3,691 |
| AbbVie | 50 | $858 |
| Actelion Pharmaceuticals US, Inc. | 9 | $500 |
| Lilly USA, LLC | 26 | $408 |
| Sanofi | 13 | $315 |
| Genentech USA, Inc. | 19 | $247 |
| Johnson & Johnson(2 entities) | 21 | $230 |
| E.r. Squibb & Sons, L.L.C. | 9 | $208 |
| GSK | 8 | $204 |
| Pfizer | 18 | $184 |
| Mallinckrodt Enterprises LLC | 8 | $112 |
| AstraZeneca | 1 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Mallinckrodt Hospital Products Inc. | 2 | $29 |
| Radius Health, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $12 |
| Medexus Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,601 in reported general payments places this provider in the 75th percentile of 102 rheumatology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 52 | $363,583 |
| Cosentyx Sensoready PenSecukinumab | 18 | $231,100 |
| Enbrel SureclickEtanercept | 29 | $223,967 |
| Taltz AutoinjectorIxekizumab | 12 | $207,645 |
| Humira(Cf) PenAdalimumab | 20 | $186,917 |
| Actemra ActpenTocilizumab | 32 | $155,574 |
| KevzaraSarilumab | 34 | $148,092 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 13 | $111,703 |
| Enbrel MiniEtanercept | 11 | $95,352 |
| Orencia ClickjectAbatacept | 13 | $73,013 |
| OtezlaApremilast | 12 | $65,343 |
| TymlosAbaloparatide | 11 | $29,309 |
| ProliaDenosumab | 15 | $25,202 |
| Mycophenolate Mofetil | 22 | $7,312 |
| MethotrexateMethotrexate Sodium | 151 | $4,050 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $858 | $363,58352 claims |
| SanofiKevzara | $315 | $148,09234 claims |
| AmgenOtezla, Prolia | $6,759 | $90,54627 claims |
| Radius Health, Inc.Tymlos | $19 | $29,30911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 102 rheumatology providers in Arizona.
Other rheumatology in Goodyear
- Nehad SolomanPhoenix$1.3M
- John TesserPhoenix$999K
- Joy SchechtmanPeoria$860K
- Mona AminGlendale$446K
- Brittany PanicoGilbert$374K
- Amer Al-KhoudariChandler$369K
- Andrew SharobeemGlendale$231K
- Paul HowardScottsdale$124K
- Sherif NasefYuma$111K
- Michael MaricicTucson$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.